Question 1

Why does a second infection with a different serotype often carry higher risk?

Accepted Answer

Cross-reactive antibodies raised by the first infection recognise the second serotype but frequently fail to neutralize it. Those complexes engage Fc receptors on monocytes and macrophages, increasing the number of infected cells and peak viral load. Higher viral burden associates with the vascular leak that defines severe disease, though host factors and viral genotype also contribute.

Question 2

Which assays measure enhancement, and what are their limits?

Accepted Answer

Enhancement is usually measured by adding diluted serum to virus and scoring infection of Fc receptor bearing cell lines against a serum-free control. The readout is real but artificial: cell lines, virus input, and dilution ranges all shift the peak. Results indicate capacity for enhancement rather than predicted clinical outcome, and should be reported with that limit stated.

Question 3

How do neutralizing antibody concentrations relate to protection versus risk?

Accepted Answer

The relationship is not monotonic. High concentrations neutralize and protect, very low ones neither protect nor meaningfully enhance, and an intermediate window carries the highest risk. Cohort work has estimated that window, but its position depends on the assay used, so titres must be anchored to a reference standard before comparison across studies.

Question 4

What cohort design supports work on serostatus-dependent outcomes?

Accepted Answer

Prospective cohorts with annual sampling and stored pre-infection sera allow antibody concentration before an episode to be linked to the outcome that follows. Enrolment must be large enough to capture rare severe cases, with active surveillance for febrile illness, molecular serotyping of each episode, and severity graded against published criteria.

Question 5

How do T-cell responses complicate an antibody-centred account?

Accepted Answer

Cross-reactive T-cell populations expand during heterologous infection and may either help control virus or contribute to inflammatory pathology, depending on epitope and prior exposure history. Projects that measure only antibodies risk attributing to them effects that are partly cellular, so including a cellular arm strengthens causal claims considerably.

Question 6

How should cross-reactivity with other flaviviruses be handled?

Accepted Answer

Serological overlap with related flaviviruses can inflate apparent dengue seroprevalence and distort estimates. Options include neutralization with a defined ratio threshold between viruses, serum adsorption against heterologous antigen, or assays targeting less conserved epitopes. Whichever route is chosen, report the misclassification it leaves rather than treating the problem as solved.

Question 7

What governance applies to vaccine-related studies in this area?

Accepted Answer

Work touching vaccine recipients or serostatus screening needs ethics approval covering how results are returned to participants, since serostatus can influence clinical decisions. Sample transfer across borders needs material transfer agreements, and virus handling follows local containment rules. Settle these before recruitment, because retrospective approval is rarely available.

Microbiology

Microbiology

Research Frontiers in Dengue Virus Serotype Cross-Immunity and Enhancement